| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 3.908 | 1.002 | 8.074 | 32.826 | 23.106 | 28.200 | 59.579 | 31.299 | 58.785 | 50.832 |
| Total Income - EUR | 3.908 | 1.003 | 8.074 | 32.874 | 23.106 | 28.200 | 59.722 | 31.551 | 58.805 | 50.832 |
| Total Expenses - EUR | 5.086 | 2.328 | 12.164 | 28.478 | 16.704 | 24.137 | 52.857 | 34.270 | 46.671 | 41.848 |
| Gross Profit/Loss - EUR | -1.179 | -1.325 | -4.090 | 4.396 | 6.402 | 4.062 | 6.866 | -2.719 | 12.134 | 8.984 |
| Net Profit/Loss - EUR | -1.296 | -1.355 | -4.171 | 4.069 | 6.166 | 3.970 | 6.345 | -2.995 | 11.576 | 8.590 |
| Employees | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Bionys Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 549 | 0 | 2.007 | 1.406 | 827 | 270 | 0 | 0 | 0 |
| Current Assets | 2.400 | 362 | 4.194 | 7.933 | 12.178 | 16.026 | 25.713 | 23.303 | 28.632 | 37.368 |
| Inventories | 17 | 0 | 3.790 | 6.895 | 5.028 | 1.203 | 503 | 3.883 | 2.689 | 3.401 |
| Receivables | 334 | 322 | 316 | 311 | 4.034 | 2.012 | -667 | -692 | 1.092 | 4.229 |
| Cash | 2.049 | 40 | 88 | 728 | 3.115 | 12.810 | 25.877 | 20.113 | 24.851 | 29.738 |
| Shareholders Funds | 811 | -553 | -4.715 | -559 | 5.618 | 9.481 | 15.615 | 12.669 | 24.207 | 32.662 |
| Social Capital | 112 | 111 | 109 | 107 | 105 | 103 | 101 | 101 | 101 | 101 |
| Debts | 1.590 | 1.464 | 8.908 | 10.499 | 7.965 | 7.372 | 10.367 | 10.634 | 4.425 | 4.707 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7500 - 7500" | |||||||||
| CAEN Financial Year |
7500
|
|||||||||
Comments - Bionys Srl